Infused antibodies are the most successful immune-based agents to treat certain cancers. However, their modes of action are not always dependent on immune mechanisms aside from antigen-specific targeting. Immune mechanisms include direct and indirect cytotoxicity while nonimmune mechanisms include the targeting of toxins, such as drugs or irradiation sources, directly to the tumor, the subject of Chap. 12. Therapeutic antibodies can be chimeric or humanized (part human and part animal, usually mouse), but fully human antibodies are in trials or have been FDA approved. This chapter will summarize the current FDA-approved antibodies to treat cancer, and highlight promising antibodies in development.
|Original language||English (US)|
|Title of host publication||Cancer Immunotherapy: Paradigms, Practice and Promise|
|Publisher||Springer New York|
|Number of pages||42|
|ISBN (Print)||9781461447320, 1461447313, 9781461447313|
|State||Published - May 1 2013|
ASJC Scopus subject areas